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ABSTRACT 
Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-
activating protein-catalysed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a 
fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on 
the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two 
new approaches to Ras pathway inhibition by stabilising or covalently modifying the Ras:SOS complex to prevent 
the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two 
distinct sites, but these compounds were not sufficiently potent inhibitors to validate our stabilisation hypothesis. We 
conclude by demonstrating that covalent modification of Cys118 on Ras leads to a novel mechanism of inhibition of 
the SOS-mediated interaction between Ras and Raf, and is effective at inhibiting the exchange of labelled GDP in 
both mutant (G12C and G12V) and wild type Ras. 
 
INTRODUCTION 
Members of the Ras family of small GTPases function as simple molecular switches. Ras is transformed into its 
active, GTP-bound state by interaction with a guanine nucleotide exchange factor (GEF) such as SOS, which 
catalyses release of GDP and allows binding of the more abundant GTP. In this active conformation, Ras is 
recognised by a range of direct effectors such as Raf, PI3 kinase and Ral proteins, which in turn can drive 
proliferation, survival and metastasis. Under normal physiological conditions, the intrinsic GTPase activity of Ras 
hydrolyses GTP back to GDP, causing inactivation. This process is significantly accelerated by GTPase activating 
proteins (GAPs) which can increase the intrinsic hydrolysis rate by up to 1000-fold. Mutations in the KRAS 
oncogene are present in a significant proportion of human tumors. Estimates of mutation prevalence vary by tumor 
type, however, they are known to be particularly associated with carcinomas of the lung, colon and pancreas.
1
 
Aberrant KRAS signaling drives an aggressive proliferative phenotype that is resistant to therapy and results in poor 
prognosis. These mutations, most commonly G12D and G12V, impair the ability of Ras to hydrolyse the terminal 
phosphate of GTP, limit sensitivity to GAP stimulation, and result in perpetual activation of Ras pathways. 
 Ras may be considered the archetypal ‘intractable target’ in oncology. Despite its characterisation over 30 years 
ago, reports on agents that directly target Ras, or indeed any GTPase, are limited.
2
 Most drug discovery efforts have 
been directed against its more tractable downstream effectors, for example inhibitors of the kinases Raf and MEK.
3
 
Guanine nucleotides exhibit picomolar affinity for Ras; therefore competitive binding at the nucleoside site is 
unlikely to be feasible, in contrast to conventional ATP mimetics in the field of kinase inhibition. It is possible that 
binding to Ras in an allosteric manner may promote loss of nucleotide, and indeed such a mechanism has been 
speculated for a reported inhibitor of the related GTPase Rac1, although no structural evidence for this is available
4
 
and no obvious structural opportunities exist for Ras. A small molecule which is able to bind to Ras-GDP and block 
SOS binding should be able to limit Ras activation. This approach to Ras inhibition via disruption of a key protein-
protein interaction has recently achieved validation by two independent groups. Sun et al. have reported a diverse 
array of small molecules that bind in a hydrophobic pocket located between the 2 helix of switch II (residues 60-
74) and the central  sheet of KRas (G12D).5 These were identified using an NMR-based screen of 11,000 fragments 
using 
15
N-labelled protein, with the binding mode confirmed by co-crystallization. 
 Simultaneously, Maurer et al. reported structurally distinct small molecules that also bind to this pocket.
6
 
Again, an NMR screen of 3,300 fragments using full-length KRas4B (G12D) yielded hits whose structures in 
complex with KRas were confirmed by X-ray crystallography. Both approaches have demonstrated that binding at 
this site in the affinity range of 100s of M is sufficient to inhibit the SOS-mediated activation of KRas. Since 
oncogenic KRas is locked in its active GTP-bound state, it is unclear whether such a strategy that prevents activation 
might be efficacious in tumors harbouring mutations in KRas, although a role in those tumors with active signalling 
through wild type Ras is plausible. Recent publications by Ostrem et al. and Lim et al. has shown that inhibition of 
the GTPase activity of the KRas(G12C) mutant can be achieved by irreversible binding of cysteine-reactive small 
molecules. Compounds are described which react close to the nucleotide binding site at Cys12, and either 
allosterically control the GTP affinity of the mutant
7
 or directly block the ability of GTP to bind.
8
 The approach 
relies on this specific KRas mutation to introduce the reactive cysteine thiolate, resulting in compounds which, while 
selective over wild type Ras, cannot inhibit other Ras mutants and which may be susceptible to resistance. 
 An alternative approach to preventing Ras activation may be envisioned in which a small molecule is able to 
bind at the interface of the Ras:SOS complex. Conceptually, such an agent might be able to stabilise these partners, 
inhibiting dissociation of SOS, and so prevent reloading of Ras with GTP. In theory this avoids some of the 
challenges implicit in other approaches, such as nucleotide competition, requiring inhibition of larger protein-protein 
interfaces, or mutant specificity, and might offer a more tractable binding pocket than the relatively featureless Ras 
protein alone. Precedent for this approach emerges from the observation that the natural product Brefeldin A (BFA) 
binds to a related small GTPase, Arf, and its exchange factor, ARNO.
9
 In this complex, GDP is also present, 
resulting in a quaternary complex where BFA is located in a hydrophobic pocket at the Arf-ARNO interface, one-
third of which is contributed by ARNO and two-thirds by Arf. BFA acts as an uncompetitive inhibitor that stabilises 
an abortive Arf-GDP-ARNO complex resulting in inhibition of the secretory pathway in eukaryotic cells.
10
 
 Compounds have recently been reported by Burns et al. which bind to the Ras:SOS complex and increase the 
rate of SOS-mediated nucleotide exchange.
11
 This is the reverse of the desired effect for an oncology therapy but it is 
notable that a small molecule can affect this pathway. 
 Although there is no reported structure of KRas in complex with an exchange factor, the structure of the closely 
homologous isoform HRas in 1:1 complex with a catalytic domain construct of SOS is known.
12
 Inhibitors of 
activation of KRas were our primary goal owing to the greater frequency of oncogenic mutations in KRas than for 
other Ras isoforms, however, molecular modelling predicted high homology to HRas in complex with SOS, so this 
was utilized as a surrogate. Indeed, in the previously described KRas fragment screen, inhibitors were reported to 
cross-react with both wild type K- and HRas.
5
 We therefore sought to use the HRas:SOS binary complex to screen 
for potential ligands via X-ray crystallography, through a process of soaking ‘cocktails’ of small fragments into 
crystals of the complex. Such an approach has been reported in inhibitor design against the bacterial enzyme 
nucleoside 2-deoxyribosyltransferase.
13
  
 
RESULTS 
X-ray screening of a fragment library 
To obtain a crystal system suitable for X-ray fragment screening, a novel co-expression construct was generated 
comprising a C-terminal truncated HRas (1-166) and the catalytic domain of SOS encompassing the Ras exchanger 
motif and cdc25 domain (564-1049). This heterodimeric protein complex was stable during purification and used to 
reproduce the structural system described by Boriack-Sjodin et al., wherein SOS has HRas bound to its catalytic 
site,
12
 while the allosteric Ras binding site described by Margarit et al. is unoccupied.
14
 
 A library of 1160 fragments was organized into four-compound cocktails using an in-house shape fingerprint 
tool to maximize the shape diversity of compounds in each cocktail.
15
 Protein crystals were soaked in a stabilizing 
solution containing a final concentration of 5 mM of each fragment for 1 hour prior to being flash frozen and stored 
for data collection using a synchrotron radiation source. Datasets were processed, structures solved and initial 
refinement carried out using in-house software pipelines. Electron density maps were visually inspected to identify 
fragment binding. We observed significant attrition where a large number of compound cocktails were observed to 
abolish diffraction from the soaked HRas:SOS crystals. Of the crystals that survived, 25% were found to have small 
molecules present at one or more binding sites on SOS and, more intriguingly, at the interface between HRas and 
SOS. We were able to determine binding affinities for the fragments identified by crystal soaking using TROSY-
HSQC solution NMR titrations with stable isotope-labeled HRas:SOS complex. A full description of the 
experimental methods used can be found in the Supplementary Results section. Crystallographic data collection and 
refinement statistics are detailed in Supplementary Table 1. 
 This paper describes three distinct small molecule binding sites that were identified on the complex, 
summarized in Figure 1.  
 Figure 1 | Three fragment binding sites on the HRas:SOS complex. HRas in green, SOS in lilac. Fragment 
binding site A (gold) is located on SOS. Site B (red) is at the HRas:SOS binding interface. On the opposite face of 
the complex, covalent binding site C (black) is found on HRas. 
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Figure 2 | Fragments binding at HRas:SOS site A. HRas colored green, SOS in lilac. Where side chain 
movements occur on ligand binding, their original positions in the HRas:SOS unbound structure 1BKD are shown in 
dark purple for comparison, with arrows indicating direction of movement. (a) Binding of 1 results in no significant 
side chain movements. (b) The binding of 2 also causes no significant side chain perturbation. (c) Upon binding of 3, 
side chain reorganization occurs at the front of the pocket opening a channel to accommodate the methylsulfanyl. (d) 
Simultaneous binding of 4a and 4b is accompanied by movement of Phe890S, opening up the back of the pocket. 
 
Fragment binding site A on SOS 
The fragment binding site we identified on the SOS protein (site A in Fig. 1) is a flexible bowl-shaped pocket lined 
with several residues showing mobile side chains. Upon binding of 1 to the SOS site A (Fig. 2a), no significant side-
chain movements are observed relative to the unbound HRas:SOS structure (PDB 1BKD). Binding appears to be 
driven by aromatic ring interactions such as the edge-face interactions of the ligand thiazole with the phenyl ring of 
Phe890 of SOS (‘Phe890S’)16 (~3.6 Å), and a π-stacking conformation between His905S (~3.8 Å) and the ligand 
phenyl ring. 
 Binding of 2 in site A occurs without significant perturbation of protein side chains (Fig. 2b). The key 
interaction is a hydrogen bond between the piperidine nitrogen and Asp887S (2.8 Å). The bromine atom of 2 is 
situated in a lipophilic pocket near His905S. 
 Binding of 3 at site A appears to be ‘shape-driven’ (Fig. 2c). An edge-face interaction is observed between 
Tyr884S and the ligand phenyl (~4 Å), and a π-stacking interaction between Phe890S and the triazine (~3.7 Å). 
Phe890S is displaced by ~1.8 Å and rotated compared with the unbound structure 1BKD. The basic nitrogen of the 
ligand piperidine forms a hydrogen bond with the carboxylic acid of Asp887S (3.0 Å). Lys898S changes from a dual 
to a single occupancy state, moving 4.3 Å to avoid a steric clash with the methylsulfanyl group of 3, with 
concomitant movement of Glu902S which forms a salt bridge with Lys898S (4.0 Å). 
 The crystal structure solved for 4a and 4b is notable because it comprises two fragments from the same cocktail 
which each bind to site A only in the presence of their partner (Fig. 2d). An NMR-derived pKD was measurable for 
each fragment independently, however, given the small number of shifts observed, especially for 4b, the binding 
sites monitored in the solution NMR experiments may not exactly coincide with that of the partnered binding 
observed in the crystal structure. In this structure Phe890S rotates 6.3 Å out towards solvent opening up a lipophilic 
pocket at the back of site A which is filled by the 4a bromine. 4b is stacked between His905S and the pyrrolidine of 
4a, whilst 4a is sandwiched between Phe890S and Tyr884S, and lies perpendicular to the plane of 4b. 
 Binding site A corresponds to the site recently reported by Burns, et al.
11
 The three X-ray crystal structures they 
describe (4NYI, 4NYJ, 4NYM) show minimal side chain movements in site A compared with the unbound structure 
of SOS, and correspond most closely with our structures of 1 and 2 in complex with HRas:SOS (Figs. 2a & 2b). 
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Figure 3 | Fragments binding at HRas:SOS site B. HRas colored green, SOS in lilac. Where side chain 
movements occur on ligand binding, their original positions in the HRas:SOS unliganded structure are shown in dark 
green for comparison. (a) 5 binds in site B at the interface between HRas and SOS, with resultant movements in 
HRas protein side chains shown. (b) 6 binding at the same location causes a larger shift in Tyr71R opening up a new 
pocket. (c) The Tyr71R side chain shows a wide range of conformations, as illustrated by an overlay of the KRas 
unbound structure 4EPR (brown), HRas:SOS unliganded structure (dark green) and HRas:SOS:6 complex structure 
(light green). (d) 5 (orange carbon atoms) binds in site B between the HRas (green) and SOS (lilac) surfaces in the 
HRas:SOS complex. In comparison, the KRas ligands 7
5
 (magenta) and 8
6
 (cyan) bind to KRas site 2 and place side 
chains into the space SOS would occupy in the HRas:SOS complex. 
 
 
 
Fragment binding site B at the HRas:SOS interface 
The binding site identified at the interface of HRas and SOS (‘site B’) corresponds to a site previously described in 
studies of uncomplexed Ras protein
5,6
 (‘site 2’). However, while Ras ligands 7 and 8, which were identified in these 
studies, inhibit SOS-mediated nucleotide exchange by preventing the binding of SOS to Ras, the fragments 5 and 6 
we identified as binding to site B interact with both Ras and SOS, and we hoped to show that this additional binding 
interaction may serve to stabilise the protein-protein interaction. 
 Fig. 3a shows 5 in complex with HRas:SOS occupying the largely solvent-inaccessible site B at the HRas:SOS 
interface. Hydrogen bonding interactions are observed between the aniline of 5 and the backbone carbonyls of 
Leu6R (3.2 Å) and Asp54R (3.0 Å). The carbonyl of the acylsulfonamide group forms an H-bond with the backbone 
NH of His911S (2.8 Å). An edge-face interaction between the phenyl ring of 5 and His911S is also observed (~3.5 
Å). The hydroxyl group of Thr74R is positioned within H-bonding distance (2.8 Å) of one of the S=O bonds of the 
acylsulfonamide. The cyclopropyl ring is positioned between to Leu56R (~3.4 Å) and Tyr912S (~3.2 Å). A 
hydrogen-bonded tyrosine bridge (3.2 Å) between the two phenols of Tyr912S and Tyr71R links HRas and SOS. 
Comparison of the unbound structure (dark green) with this ligand-bound Ras:SOS complex shows limited 
movement for the majority of protein side chains in this region, with some notable exceptions. Thr74R moves 2.4 Å, 
making room for the ligand phenylsulfonamide. A small movement in the associated -helix (residues Gln70R-
Thr74R), opens up the binding pocket slightly. Tyr71R is displaced by 1.1 Å, accommodating the cyclopropyl group 
of 5, however, it remains within H-bonding distance of Tyr912S. In contrast to HRas, SOS residues are unperturbed 
upon binding of 5. 
 Synthesis of analogues of 5 led to acylsulfonamide 6 (Fig. 3b). Similar interactions are seen with Leu6R, 
Asp54R, and His911S. Compared with 5, the distance between Thr74R and the S=O group of 6 increases to a range 
no longer conducive to hydrogen bonding. Lys5R rotates and moves ~4 Å. However, most notable is the movement 
of Tyr71R, which flips from the position observed in the unbound structure, where it forms a tyrosine bridge with 
Tyr912S, to an alternative location at the back of the pocket.  This likely results from the increased steric bulk of the 
piperidinone ring of 6 compared with the isopropyl of 5. The Tyr71R phenol OH moves 8.1 Å, opening up a new 
cavity which is occupied by a number of water molecules. Figure 3c shows the wide range of movement observed 
for the Tyr71R side chain amongst Ras structures. In unbound KRas (brown) the phenol group overlaps with site B. 
In the HRas (dark green):SOS (lilac) complex, Tyr71R forms a tyrosine bridge with Tyr912S and creates a pocket 
between the two proteins into which compounds such as 5 may bind. Increasing the size of the small molecule 
ligand, such as in 6 (grey), is accompanied by further movement of Tyr71R (light green), opening up a larger binding 
pocket between the two proteins. Disruption of the HRas:SOS tyrosine bridge does not significantly alter the binding 
affinity of the fragments (Table 1). 
 X-ray crystal structures of ligands binding solely to Ras have been published since the work described in this 
paper was completed.
5,6
 Comparison of published crystal structures with that of the HRas:SOS:5 complex shows that 
site B corresponds with the relatively shallow ‘binding site 2’ of the published fragments 7 and 8 on KRas (Fig. 3d). 
Compound 5 interacts with HRas through its acylsulfonamide motif, while the corresponding space is left 
unoccupied by 7 and 8, which instead extend beyond the confines of site B and place polar groups in the spaces 
occupied by Tyr912S and His911S in the HRas:SOS complex. The resulting steric clash with SOS seems likely to 
contribute to the inhibition of nucleotide exchange that has been reported for 8.
6
 
 
The challenge of obtaining biological activity 
While we demonstrated binding of fragments at sites A and B by X-ray crystallography, and were able to quantify 
their binding affinities by NMR, this did not translate into a measurable effect on nucleotide exchange (vide infra). 
This was not surprising, since we anticipated more potent compounds would be required to show functional activity. 
We synthesized analogues of 1 and 5, varying both substituents of the sulfonamide. The most interesting compound 
identified was 6, where the site B binding pocket was expanded. We also made analogues of triazine 3, varying the 
heteroatoms in the triazine ring, switching the thiomethyl group, and varying the piperazine side chain. We found 
that the basicity of the piperazine ring was critical to maintain the high levels of solubility required for screening and 
crystallization at high concentrations. However, after several rounds of chemistry optimization, we were unable to 
improve the affinity of these hits significantly or demonstrate that such small ligands were measurably able to 
stabilize the Ras:SOS complex.  
 A growing body of literature suggests that use of a ligand which binds covalently to a protein target may offer a 
way to permanently deactivate protein function.
7,8,17,18,19
 Considering the picomolar affinity of Ras for GDP, we 
hypothesised that an irreversible inhibitor may afford the only realistic chance of inhibiting GTPase activity. We 
identified Cys118R in the HRas:SOS complex as a potentially reactive protein side chain proximal to the GDP 
binding site on HRas (site C in Fig. 1) and set out to discover fragments which would irreversibly bind to it. This 
cysteine residue is conserved between HRas and KRas. 
 
4a 
 
4b 
 
4c
 
4d
 
Figure 4 | Fragments binding at HRas:SOS site C. HRas colored green, SOS lilac. Where side chain movements 
occur on ligand binding, the relevant side chains from the HRas:SOS unbound structure 1BKD are shown in dark 
green for comparison. (a) Covalent binding of 9 (represented by a magenta line) restrains the otherwise flexible side-
chain of Cys118R into a single conformation. (b) Covalent binding of 10 causes Cys118R to adopt a different side-
chain rotamer to that observed on binding of 9, allowing the targeting of a new growth vector, marked by *. (c) The 
meta-substituents of 11 (dark grey) and 12 (light grey) follow a similar path down a lipophilic channel on Ras. (d) 
Overlay of HRas:SOS (green/lilac) in complex with 12 (grey) on the PDB KRas structure 4DSO shows that 12 
occludes the GDP (cyan) binding site on KRas (brown). A dramatic shift is seen in the position of Cys118 of KRas 
compared with Cys118R of the HRas:SOS:12 complex. 
 
 Irreversible binders at HRas:SOS site C 
A library of 400 compounds was selected, comprising members with fragment-like properties
20
 (MWt  300, cLogP 
1-3, cLogD -1 to 3,  2H-bond donors,  6 H-bond acceptors,  2rings,  6 rotatable bonds and 20 heavy atoms) 
and potentially reactive functional groups. These were identified from reports in the literature
21
 and by mining the 
data from an in-house glutathione reactivity assay,
22
 in which compounds with half-lives in the range of 15-3000 
minutes were judged to be suitably reactive. Typical chemotypes represented in the library are shown in Table 2. 
Compounds were screened by mass spectrometry, by observing the mass increase of the HRas:SOS complex 
following compound addition. 
 We selected the reactive N-ethylmaleimide (NEM) group as an ideal electrophilic ‘warhead’ to bind to 
Cys118R. Other warheads were deemed either insufficiently reactive (giving incomplete cysteine adduction) or too 
reactive (reaction with multiple cysteine or histidine residues on the HRas:SOS complex) to progress. Using X-ray 
crystal structures of the HRas:SOS:inhibitor complex to guide design, we anticipated that building constructive non-
covalent binding interactions with the protein (i.e. increasing Ki) might allow replacement of the maleimide with a 
less reactive motif (i.e. reducing Kinact) whilst retaining overall inhibitory activity.
23
 Substitution of the maleimide 
double bond offered the possibility of modulating the electrophilicity of the Michael acceptor warhead, once 
additional non-covalent interactions had been identified. 
 Promising hits from the mass spectrometry screen of reactive fragments included N-substituted maleimides 9 
and 10. X-ray crystal structures obtained subsequently showed 9 (Fig. 4a) and 10 (Fig. 4b) binding with a distance 
of 1.8 Å between the ligand C-3 and the Cys118R sulfur atom, and continuous electron density, confirming that a 
covalent bond is formed between ligand and protein (Supplementary Fig. 1). Interestingly, the pyrrolidine-2,5-dione 
rings in 9 and 10 were observed to adopt different orientations. The C-4 atom in 10 presented an ideal vector for 
growing the fragment into a lipophilic channel (indicated with * in Fig. 4b), and a set of analogues was synthesized 
to vary at this position. Analogues 11 and 12, which carry a meta-substituted phenyl ring at C-4, were successfully 
crystallized with HRas:SOS, adopting similar binding modes in which the C-4 substituent extends down a lipophilic 
groove adjacent to Glu942S (Fig. 4c). With a meta-substituent effectively anchoring the pendant phenyl group in one 
orientation, compounds 13 and 14 were designed to probe interactions with Glu942S, via a bis-3,5-substituted ring. 
 Comparison of the published KRas:GDP crystal structure 4DSO and our HRas:SOS structures shows 
reorganization of the GDP binding pocket following association of Ras and SOS (Fig. 4d). This reconfiguration 
involves Cys118R, which is otherwise buried in the interior of the KRas:GDP complex where it may be somewhat 
protected from electrophiles. When SOS binds to Ras and displaces GDP, the Cys118R residue is exposed to solvent, 
rendering it more vulnerable to reaction with 9-14. Once such a reaction has occurred, the covalently-bound 
fragment partly occludes the nucleotide binding site and could potentially also prevent reorganization of the 
Cys118R loop of Ras, thus locking the protein into the catalytically inactive Ras:SOS complex.  
 As we had hoped, fragments which covalently modified HRas in the crystal environment also demonstrated 
functional activity in preventing wild type KRas activation. Due to the spectral properties of these compounds it was 
not always possible to use previously-reported methods for monitoring nucleotide exchange with MANT-labeled 
GDP
6
 as many of the compounds interfered with the excitation/emission spectra. Therefore, a novel homogeneous 
time-resolved fluorescence (HTRF) assay was designed to profile this series. In this homogenous assay, biotin-
KRas:GDP was labeled with streptavidin europium and GST-Raf was labeled with anti-GST XL665. Activation of 
KRas was initiated with the addition of SOS and GTPS. Upon binding of the active GTPS-bound 
streptavidin:biotin-KRas to Raf-GST:Anti-GST XL665, the europium donor and XL665 acceptor are brought into 
close proximity resulting in an increased acceptor emission at 665 nm (Supplementary Fig. 2). 
 Compounds 10-14 were pre-incubated with either KRas:GDP, SOS alone or a KRas:GDP:SOS mixture for 2.5 
hours to allow the compound to react, then inactivated by the addition of dithiothreitol (DTT). All samples were then 
made up to contain the same concentrations of KRas:GDP and SOS, and incubated with streptavidin-europium for 4 
hours. In a separate reaction GST-Raf was incubated with anti-GST XL665. The exchange reaction was initiated by 
the addition of GTPS and GST-Raf. The activation of KRas was then monitored via HTRF between the 
streptavidin-europium and XL665 upon binding of active KRas to GST-Raf. 
 Complete inhibition of KRas activation was achieved only when 10-14 were pre-incubated with 
KRas:GDP:SOS (Fig. 5), which supports the hypothesis that Cys118R becomes more accessible during the 
conformational changes which occur during SOS-mediated nucleotide exchange. Neither pre-incubation of 11-13 
with KRas:GDP with subsequent addition of SOS nor pre-incubation with SOS followed by addition of KRas:GDP 
led to significant inhibition of the Ras-Raf interaction. A modest degree of KRas inhibition (~40-50%) was observed 
when 10 and 14 were pre-mixed with KRas alone. This may be due to the increased reactivity of the Michael 
acceptors in these molecules causing them to behave in a less specific manner, as we had observed during the initial 
irreversible fragment screening campaign; 10 is an unsubstituted maleimide and 14 has two strong electron 
withdrawing groups on its phenyl ring. The inhibitory effects of 10-14 could be eliminated by the addition of DTT (1 
mM) during the pre-incubation step, presumably because DTT reacted with the maleimide warhead before it was 
able to irreversibly modify the KRas:SOS complex. 
 
 
Figure 5 | Inhibition of KRas:SOS functional activity by irreversible inhibitors. Compounds 10-14 (200 µM) 
were pre-incubated with either GDP-loaded Biotin-KRas alone (blue), GDP-loaded biotin-KRas plus SOS (red) or 
SOS alone (green). All samples were then made up to contain the same concentrations of KRas:GDP and SOS. 10-14 
caused complete inhibition of functional activity when pre-mixed with KRas:GDP and SOS together, but modest or 
no inhibition when pre-mixed with KRas:GDP or SOS alone. No inhibition was observed with non-covalent 
compounds 1, 3 or 5 (data not shown). Error bars show one standard deviation. Comparison of KRas and KRas:SOS 
data using the unpaired T-test shows all results to be statistically significant, p<0.0001 (****). Full data are shown in 
Supplementary Table 2. 
 
Site C irreversible binders show time-dependent inhibitory activity against both wild type and mutant KRas  
The inactivation of wild type KRas, KRas(G12V) and KRas(G12C) was monitored using a MANT-dGDP assay and 
a fluorescence assay-compatible compound, 12. Initially, the KRas constructs were pre-equilibrated with MANT-
dGDP to replace the bound unlabelled nucleotide which co-purifies with KRas. All three constructs then underwent 
SOS-mediated nucleotide exchange which resulted in an increase in fluorescence upon MANT-dGDP binding. At 
equilibrium, the reaction cycled between the MANT-dGDP and the unlabelled nucleotide. Upon the addition of 12 
(200 M), time dependent inactivation of each of the KRas constructs was observed (Fig. 6). An excess amount of 
unlabelled GDP was included as a control to compete with the MANT-dGDP resulting in a loss of fluorescence. 
Since the rate of reduction of fluorescence is similar with the addition of either excess GDP or irreversible inhibitor 
12, this supports the hypothesis that nucleotide exchange is driven in both cases by the rate of association of 
Ras:SOS. If excess GDP is present, SOS associates with Ras, the MANT-dGDP is displaced, and is then replaced 
with unlabelled GDP when SOS dissociates. If 12 is present when SOS associates with Ras and displaces MANT-
dGDP, the resulting KRas:SOS, KRas(G12V):SOS or KRas(G12C):SOS complex reacts with the irreversible 
inhibitor at Cys118R, forming a dead-end complex which prevents the subsequent re-binding of MANT-dGDP. 
 
Figure 6 | Inhibition of SOS-mediated MANT-labelled nucleotide exchange by 12 in a range of Ras mutants. KRas wild 
type, KRas(G12V) and KRas(G12C) were equilibrated with MANT-dGDP which is environmentally sensitive and significantly 
increases in fluorescent quantum yield when protein bound. 12 was added (200 µM) and inactivation was monitored over time. A 
reduction in fluorescence was observed against all three KRas constructs (red, blue and purple lines). An excess of GDP was used 
as a control to compete off the MANT-dGDP (green line). Color-coded error bars for measurements are also shown. Full data are 
shown in Supplementary Table 3. 
 
DISCUSSION AND CONCLUSIONS 
Our work with non-covalent fragments showed that it was possible to characterize compounds from multiple series 
binding on SOS and at the HRas:SOS interface, however, none of these compounds were sufficiently potent to show 
functional activity in the Ras:Raf HTRF assay. Synthesis of analogues of 1, 3, 5 and 6 led to compounds with similar 
binding affinities to the parent fragments and unproductive SAR. The report by Burns et al. that small molecules 
which bind at SOS site A cause an increase in the rate of SOS-mediated nucleotide exchange
11
 was not corroborated 
by experiments with our fragments, suggesting that more dramatic changes or hybridization of series may be 
required to achieve sufficient binding affinity. While we were not able to detect functional biological activity for the 
probes identified at sites A and B, we believe that our observations of specific ligandable
24
 interaction points may 
suggest a potential way forward using larger molecules such as macrocycles
25
 or constrained peptides.
26 
The distance 
between the closest atoms on non-covalent fragments bound in sites A and B is 9.1 Å. Precedent for linking distant 
fragment sites suggests that connecting two weak fragments can bring very large increases in potency, but is most 
likely to succeed when fragments are significantly closer together than sites A and B. If fragment ligands for sites A 
and B could be iteratively grown towards each other, however, this strategy may be more likely to succeed.
27
 
 While our efforts to inhibit Ras by stabilization of the Ras:SOS complex by fragments binding in a reversible 
manner were unsuccessful, we showed that reactive fragments which covalently modify site C near to the nucleotide 
binding site were effective Ras inhibitors. We demonstrated complete inhibition of KRas:SOS functional activity 
following reaction of maleimides 10-14 with Cys118R, a previously undescribed method of inhibition of Ras. A 
synthetic chemistry campaign led to fragments which showed a consistent binding mode at site C, and resulted in 
inhibition of wild type KRas in a novel HTRF assay measuring the Ras-GTP:Raf interaction. Several potential 
vectors were identified for further growth of these inhibitors; for example, along the lipophilic channel from the meta 
position of phenyl groups in 11-14, or from the maleimide N-substituent towards SOS. 
 An important objective for a covalent approach to Ras:SOS inhibition is to reconcile the need to measure 
variations in potency of molecules – and hence structure-activity relationships – with the requirement for a warhead 
of high reactivity necessary to observe any inhibitory activity. With the fragment series based on maleimides, 
although it was possible to measure potency and inhibition of nucleotide exchange, this measure was driven largely 
by Kinact, and small changes in Ki were difficult to detect. The determination of Ki changes is important to assist the 
design of more potent, but less reactive inhibitors. Tuning the reactivity of the covalent modifier by modulating the 
electrophilicity of the Michael acceptor warhead could potentially be achieved by using an electron-donating linker 
such as ether or amine. Kathman et al. recently published an example of this approach being used successfully 
against a cysteine protease.
28
 
 Our work has explored three small molecule binding sites on the Ras:SOS complex, and details synthetically 
accessible small molecule probes that bind at each site. We demonstrated inhibition of KRas functional activity with 
compounds which bind irreversibly at site C, and showed that covalent binding with HRas in a protein crystal 
environment translates to nucleotide exchange inhibition in the more oncology disease-relevant isoform KRas. 
Furthermore, this mechanism of KRas inactivation appears to be applicable to mutant forms of KRas which also 
share a Cys118 residue, such as KRas(G12C) and KRas(G12V). Although significant work remains to optimize the 
biological activity of the compounds we have described at site C, our discoveries open the way to a new strategy to 
target aberrant Ras signalling by intervening in the SOS-mediated activation of Ras. 
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13 R1 = COOH 
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Table 1 | Structure and NMR binding KD of HRas:SOS ligands. The crystal structures for HRas:SOS:compound 
complexes are deposited in the Protein Data Bank (PDB, http://www.rscb.org) under the accession codes above. 
Values for KD determined by NMR chemical shift mapping are shown with the standard error of the mean for each 
measurement. a Significant precipitation was observed. b 4a and 4b only bound when both ligands were present in the 
same cocktail. c KD measurements were not generated for the literature compounds 7 & 8, which bind to Ras alone, 
or covalently bound compounds 9 – 14. d See reference 5. e See reference 6. 
  
 Table 2 | Examples of reactive functional groups represented in the covalent fragment library. R indicates any 
functional group.a See reference 21. b See reference 22. 
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References 
Nuclear magnetic resonance KD determinations. Samples of 6His-TEV-SH-HRas(1-166) and 6His-TEV-SH-SOS 
uniformly labeled with 
2
H,
15
N were produced in E. coli using M9 minimal media supplemented with 5 g/L Celtone 
base powder (
2
H, 97%, 
15
N, 98%; Cambridge Isotope Laboratories Inc.), yielding 15 and 150 mg/L of purified 
protein, respectively. The purification was via NiNTA, TEV cleavage and dialysis, subtractive NiNTA to remove the 
tag and size exclusion chromatography (SEC) using a Superdex 200 column. After cleavage, both proteins were left 
with GSH residues preceding the protein sequence. A 16-fold excess of GTPS was added to the HRas sample to 
achieve exchange of bound nucleotide, and was then left at room temperature overnight to equilibrate before passing 
down a PD10 column to remove excess nucleotide. The 2:1 HRas:SOS complex was formed by adding 
HRas(GTPS) and SOS from concentrated stocks (~0.8 mM) to obtain 0.5 mL of 0.16 mM HRas and 0.08 mM SOS 
in 50 mM HEPES (pH 7.4), 50 mM NaCl, 2 mM TCEP, 2 mM MgSO4, 0.1 mM EDTA and 0.02 % NaN3. NMR 
spectra were collected at 298 K on a Bruker Avance 600 MHz spectrometer running TopSpin 2.1, equipped with a 5 
mm TCI Cryoprobe with Z-axis gradients. The complex was titrated with compound stocks (typically at 200 mM) to 
give final compound concentrations of 0, 0.2, 0.6, 1.4, 3.4 and 7.4 mM; these were measured using 2D 
1
H,
15
N-
TROSY-HSQC
29
 experiments recorded with 2048x50 (t2,t1) complex points (in Echo-Antiecho mode), and 
12019x2068 Hz (
1
H,
15
N) spectral widths, (85.3 ms x 24.2 ms acquisition times, respectively). The affinity of the 
compounds was determined via simultaneous nonlinear fitting of fast-exchange chemical shift perturbations 
(typically 5 amide correlations, employing the absolute value of the linear 
1
H,
15
N chemical shift vector) against 
compound concentration using a mass action binding isotherm equation. 
 
Mass spectrometry analysis of covalent adduction to proteins. The HRas:SOS complex was prepared by pre-
incubating the purified recombinant HRas with GTPS (>10 fold molar excess). Both HRas and SOS proteins were 
transfered individually by gel filtration chromatography into ammonium acetate buffer (20 mM, pH 6.8). Their 
concentrations were estimated by UV absorbance at 280 nm (NanoDrop, Thermo, Wilmington, DE, USA), before 
combining the two protein solutions in a stoichiometric ratio of ~2:1 (Ras:SOS) to give final protein concentrations 
of ~19 µM and ~10 µM respectively. Fragment-like compounds were prepared as solutions at a concentration of 10 
mM in either ethanol or acetonitrile. Compound solutions (180 nL) were added to protein solutions (3.25 µL) and 
S3 
 
mixed using 10 cycles of aspiration and re-dispensing (Mosquito HTS, TTPLabtech, Hertfordshire, UK). Incubation 
(2 hours at room temperature) was in sealed 384-well plates. Automated analysis was performed by sampling 
directly from the incubation plate and infusing using an Advion Nanomate (Advion, Ithaca, NY, USA) mounted on 
the source of a QToF mass spectrometer (QToF Micro, Waters, Manchester, UK). Data acquisition (~2 minutes) for 
each sample was initially under non-denaturing ionisation conditions, changing to denaturing conditions 
approximately halfway through the acquisition. Data were interpreted manually. Those data obtained under 
denaturing conditions detected quantitative covalent adduction of compound to the individual HRas and SOS 
subunits. Any observed delta mass increase was calculated (multiplying the  m/z by the protein charge state) and 
validated by comparison with the expected mass increase resulting from the predicted reaction mechanism of the 
compound. Data obtained under non-denaturing conditions detected covalent adduction, and also modulation of the 
protein complex quantitative distribution. 
 
Crystallographic system. A dual expression vector encoding HRas 1-166 with an N-terminal TEV protease 
cleavable hexa-histidine tag and untagged SOS
cat
 564-1049 was used to direct expression of the HRas:SOS complex 
in E.coli. Following cell lysis, the clarified lysate was batch bound to a nickel NTA resin using a buffer comprised of 
40 mM HEPES (pH 8.0), 300 mM NaCl, 20 mM imidazole and 2 mM β-mercaptoethanol, and finally eluted with a 
step gradient of 500 mM imidazole. The eluted complex was incubated overnight in the presence of TEV protease to 
remove the affinity tag, whilst dialyzing against a buffer comprised of 40 mM HEPES (pH 8.0), 300 mM NaCl and 2 
mM -mercaptoethanol to reduce the imidazole concentration to 20 mM. Reverse affinity purification was performed 
to remove the protease and uncleaved material. This was followed with a gel filtration chromatographic step using a 
Superdex 200 column run in a final buffer of 20 mM TRIS (pH 8.0) and 100 mM NaCl. The peak containing the 
HRas:SOS complex was pooled, concentrated to 11 mg/mL, and stored at -80 °C. Protein crystallisation was 
performed using sitting drops at room temperature with 1:1 ratios of protein complex to a mother liquor comprised of 
3.8-4.0 M sodium formate and 0.1 M TRIS (pH 8.0). Crystals appeared within a few days and grew to their final size 
in 1-2 weeks. Cocktail soaking was performed by transferring crystals into a solution containing 4.5 M sodium 
formate, 5% glycerol and a total cocktail concentration of 50 mM in 20% DMSO, representing 12.5 mM of each 
fragment. Following one hour exposure, crystals were harvested and frozen for data collection. For single compound 
soaks, a soaking solution of 4.5 M sodium formate, 0.1 M TRIS (pH 8.0) and 5% glycerol was used with a final 
S4 
 
concentration of compound at 10 mM, 10% DMSO. Data were collected at both the European Synchrotron Radiation 
Facility in Grenoble, France, and Diamond Light Source, Oxford, UK. The search model used during structure 
solution was 1BKD. A combination of software from the CCP4 suite
30
 and the Global Phasing Consortium
31,32
 was 
used to process the data, and solve and refine the structures. Manual model completion in Coot
33
 was used to 
generate the final models for design. Supplementary Figure 1 shows an example of electron density that was 
collected. 
 
Supplementary Figure 1 | Example of electron density data collected. An example of 2Fo-Fc electron density for 
the covalent addition of small molecules to cysteine 118 of HRas. HRAS and SOS
cat
 are depicted with cyan and 
orange carbon atoms respectively.  The refined final map is contoured at 1σ. 
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  4URU 4URV 4URW 4URX 4URY 4URZ 4US0 4US1 4US2 
Data collection 
         
Space group I422 I422 I422 I422 I422 I422 I422 I422 I422 
Cell dimensions 
         
    a, b, c (Å) 
149.28, 
149.28, 200.52 
149.90, 149.90, 
200.20 
149.41, 149.41, 
200.34 
149.87, 149.87, 
199.70 
149.68, 149.68, 
200.18 
150.21, 
150.21, 
201.62 
149.22, 149.22, 
201.04 
149.56, 149.56, 
199.64 
149.71, 149.71, 
200.08 
 ()  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 120 (2.83) * 50.0 (2.58) * 120 (2.76) * 120 (2.48) * 120 (2.47) * 120 (2.24) * 120 (2.17) * 50 (2.65) * 53 (2.48) * 
Rsym or Rmerge 0.068 (0.478) 0.091 (0.746) 0.099 (0.503) 0.056 (0.506) 0.076 (0.489) 0.074 (0.49) 0.063 (0.479) 0.121 (0.865) 0.116 (0.759) 
 30.7 (5.6) 15.9 (2.5) 12.7 (3.3) 33.4 (5.1) 17.7 (4.6) 17.1 (3.6) 33.2 (6.4) 13.7 (2.3) 11.6 (2.5) 
Completeness (%) 100 (100) 97.6 (99) 100 (100) 100 (100) 91.9 (94.7) 90.5 (91.4) 100 (100) 92.9 (94.3) 97.3 (99.0) 
Redundancy 12 (12.3) 6.8 (6.9) 6.7 (6.2) 12 (11.3) 7.9 (7.8) 7.2 (7.1) 13.9 (14.1) 7.2 (7.2) 6.9 (6.8) 
          
Refinement 
         
Resolution (Å) 2.83 2.58 2.76 2.49 2.47 2.25 2.17 2.65 2.48 
No. reflections 27366 35039 29346 40039 37338 50173 59613 30842 39224 
Rwork / Rfree 19.2 / 23.7 19.5 / 23.2 18.2 / 23.0 19.5 / 22.6 19.4 / 22.9 19.1 / 21.2 18.7 / 21.2 19.3 / 23.1 19.2 / 22.8 
No. atoms 
         
    Protein 5053 5034 5058 5043 5029 5065 5063 5072 5060 
    Ligand/ion 17 20 22 26 32 17 9 17 18 
    Water 71 198 201 195 183 247 493 178 301 
B-factors 
         
    Protein 60.4 54.4 46.7 55.4 54.6 54.2 42 51.4 50 
    Ligand/ion 76 72.9 46.2 60.2 67.4 59.3 56.2 74.9 71 
    Water 47.5 47.4 39.6 50.3 50.2 52.4 47.8 42.4 47.2 
R.m.s. deviations 
         
    Bond lengths (Å) 1.436 1.435 1.417 1.422 1.404 1.441 1.408 1.414 1.414 
    Bond angles () 0.015 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 
Supplementary Table 1 | X-ray crystallographic data collection and refinement statistics. All structures were solved using data from a single crystal. 
* Values in parentheses are for highest-resolution shell.
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Ras:Raf HTRF assays. Reagents were diluted in 20 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 0.01% Tween-
20 (exchange buffer) unless otherwise noted. Results are given in Supplementary Table 2. A graphical 
representation of this assay can be found in Supplementary Figure 2. 
KRas premix variant. A-1. In a low volume 384 well plate (Greiner 784904) 1 µL of compound (1 mM in 
DMSO, 200 M final during the pre-incubation step) was incubated with 4 µL biotinylated-KRas-GDP (15 nM 
in exchange buffer). The reaction was incubated for 2.5 hrs at ambient temperature and then 1 µL of streptavidin 
europium (Cisbio, 610SAKLB) (750 ng/mL in exchange buffer additionally containing 20 mM DTT), was 
added. Finally, 4 µL SOS (5 µM in exchange buffer) was added. This mixture was incubated for 4 hours to allow 
the detection reagents to equilibrate. 
B. In a separate 1.5 mL reaction GST-Raf (20 nM) was added to with anti-GST XL665 (4 µg/mL, Cisbio, 
61GSTXLA) in exchange buffer additionally containing potassium fluoride (0.1 M) and BSA (0.01% w/v). This 
mixture was incubated for 4 hours to allow the detection reagents to equilibrate.  
C. 3 µL GTPS (1 mM in exchange buffer) was added to sample B and a 10 µL sample of B+GTPS was added 
to each well of A-1 to initiate nucleotide exchange. Final assay concentrations were 3 nM biotin-KRas, 1 µM 
SOS, 1 µM GTPS, 10 nM GST-Raf, 2 µg/mL anti-GST-XL665 and 37.5 µg/mL streptavidin europium. The 
plate was read after 60 minutes using an EnVision plate reader (Perkin Elmer) with an excitation wavelength of 
320 nm, emission wavelengths of 615 nm and 665 nm, and the data was normalized to the donor emission (615 
nm/665 nm x 10
4
). An increase in the emission ratio was detected when the europium and XL665 were brought 
into close proximity by the binding event between activated KRas and Raf. Inhibition values were calculated 
from control DMSO samples containing no compound (0 % inhibition) or no biotin-KRas (100% inhibition). 
KRas:SOS premix variant. A-2. In a low volume 384 well plate (Greiner 784904) 1 µL of compound (2 mM in 
DMSO, 200 M final during the pre-incubation step) was incubated with 4 µL biotinylated-KRas-GDP (15 nM 
in exchange buffer) and 5 µL SOS (4 µM in exchange buffer). The reaction was incubated for 2.5 hrs at ambient 
temperature and then 1 µL of streptavidin europium (Cisbio, 610SAKLB) (750 ng/mL in exchange buffer 
additionally containing 20 mM DTT), was added. This mixture was incubated for 4 hours to allow the detection 
reagents to equilibrate. Mixture B was prepared and added to A-2 as previously described in step C (vide supra). 
SOS premix variant. A-3. In a low volume 384 well plate (Greiner 784904) 1 µL of compound (1 mM in 
DMSO, 200µM final during the pre-incubation step) was incubated with 4 µL SOS (5 µM in exchange buffer). 
The reaction was incubated for 2.5 hrs at ambient temperature and then 1 µL of streptavidin europium (Cisbio, 
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610SAKLB) (750 ng/mL in exchange buffer additionally containing 20 mM DTT), was added.  Finally, 4 µL 
biotinylated-KRas-GDP (15 nM in exchange buffer) was added. This mixture was incubated for 4 hours to allow 
the detection reagents to equilibrate. Mixture B was prepared and added to A-3 as previously described in step C 
(vide supra). 
Assay statistics. The assay data varies depending on the pre-incubation conditions (A-1, A-2 or A-3) but typical 
values are in the ranges shown below: 
 Signal to noise = 9 – 28 
 Signal to background = 2.8 – 4.3 
 % CV = 3.6 – 11.5 
 Z’ = 0.51 – 0.83. Depending on the exact format used Z’ values of  >0.7 are routinely achieved. 
 Range and sensitivity: The theoretical tight-binding limit for compounds targeting KRas is  ~1.5 nM, 
and for SOS binders is 500 nM. 
Comment on the high concentration of SOS. The rate of nucleotide exchange will be determined by many 
factors including the affinity of SOS for the nucleotide bound KRas, the rate of dissociation of GDP, association 
of GTP, dissociation of SOS and subsequent binding of active KRas to the Raf to generate the HTRF signal. 
Therefore a pragmatic approach was taken and the SOS was simply titrated into the assay and the initial rate of 
exchanged was monitored. The concentration selected was approximately half the maximum rate measured. This 
is analogous to the Km of an enzyme reaction. The 60 minute endpoint selected was on the linear part of the 
exchange curve. The 1 M SOS used is not inconsistent with other groups using the MANT assay but this HTRF 
assay is more sensitive and enables the KRas concentration to be much lower than is required for the MANT 
assay. 
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Supplementary Figure 2 | Schematic representation of the HTRF assay. (a) Step A: Compound pre-
incubation. Test compounds were pre-incubated with either GDP:biotinylated KRas alone (A-1), 
GDP:biotinylated KRas + SOS (A-2) or SOS alone (A-3) for 2.5 hours. Mixtures of GDP, Ras and SOS are 
assumed to be in equilibrium as Ras:GDP and Ras:SOS but for simplicity are depicted as a single complex in the 
figure. (b) KRas and SOS concentrations in the three sets of pre-incubation conditions were normalized and 
streptavidin-europium added to each sample. (c) Step B: GST-Raf and anti-GST were mixed and incubated for 4 
hours to allow the detection reagents to equilibrate. (d) Step C: KRas activation and detection. SOS-mediated 
nucleotide exchange and detection was initiated by the addition of the GTPS and simultaneous addition of Raf-
1/XL665. (e) KRas:GTPS is detected upon binding to GST-Raf1-RBD which brings the streptavidin-europium 
and anti-GST-XL665 into close proximity. Compounds which bind to KRas or stabilise the KRas:SOS complex 
and prevent nucleotide exchange will result in loss of the HTRF signal. 
 
Pre-incubation   
Compounds Controls 
10 11 12 13 14 DMSO No KRas 
A-1: 
KRas:GDP 
Measurements 
48.430, 
35.594, 
40.193 
14.598, 
-7.689, 
-1.225 
7.418, 
-18.160, 
-1.557 
19.557, 
12.439 
51.6107, 
47.1189, 
44.8484 
1.352, -2.447, 
5.955, -4.861 
99.485, 
101.008, 
99.508 
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Mean 41.4 1.9 -4.1 16.0 47.9 0.0 100.0 
Stdev 6.5 11.5 13.0 5.0 3.4 4.7 0.9 
A-2: 
KRas:GDP + 
SOS 
Measurements 
99.506, 
102.565, 
101.045 
98.255, 
96.861, 
94.349 
100.245, 
98.688, 
98.279 
101.077, 
98.247, 
99.179 
101.611, 
100.305, 
100.471 
2.075, 22.415, 
13.311, 
-18.098, 
-15.954, -3.749 
99.533, 
100.288, 
100.188 
Mean 101.0 96.5 99.1 99.5 100.8 0.0 100.0 
Stdev 1.5 2.0 1.0 1.4 0.7 16.0 0.4 
A-3: SOS 
Measurements 
2.154, 
-10.344, 
-25.342 
-21.796, 
-18.857 
-13.096 
-36.586, 
9.190, 
17.839 
19.165, 
24.963, 
44.560 
-10.967, 7.401, 
5.181, -1.615 
100.291, 
98.218, 
101.495 
Mean -11.2 -20.3 -13.9 -3.2 29.6 0.0 100.0 
Stdev 13.8 2.1 n/a 29.2 13.3 8.3 1.7 
 
p Values 
Compounds 
10 11 12 13 14 
A-1 : A-2 0.0001 0.0001 0.0002 0.0001 <0.0001 
A-2 : A-3 0.0001 <0.0001 - 0.0037 0.0008 
A-1 : A-3 0.0039 0.0819 - 0.4467 0.0824 
 
Supplementary Table 2 | Inhibition of KRas:SOS functional activity by irreversible inhibitors 10-14. 
Inhibition of functional activity was measured following 2.5 hour pre-incubation of 10-14 with either KRas 
alone, a KRas:SOS mixture, or SOS alone. The mean and standard deviation of measurements are given, except 
for the SOS/12 experiment where only one measurement was obtained due to a dispensing failure. p Values are 
shown comparing each of the three assays with one another. 
 
MANT-dGDP nucleotide exchange assays. Reagents were diluted in 20 mM HEPES, 150 mM NaCl, 5 mM 
MgCl2, 0.01% Tween-20. Results are given in Supplementary Table 3. 
MANT-dGDP pre-equilibration. In three separate 400 L reactions, KRas (1 M), KRas(G12V) (1 M) and 
KRas(G12C) (1 M) were each incubated with SOS (2 M) and MANT-dGDP (1.5 M) (2'-Deoxy- 3'-O-(N'-
methylanthraniloyl)guanosine-5'-O-diphosphate,  Biolog Life # D084-05). The reactions were incubated for 4 
hours to allow the MANT-dGDP to equilibrate with the unlabelled GDP bound to the purified KRas. 
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KRas inactivation. To monitor the inactivation of KRas, 6 L of 12 (as a 400 M solution) was added to a 
black 384 well plate (Greiner 748900). A portion of the equilibrated KRas:SOS:MANT-dGDP mixture (6 L) 
was added to 12 (for a final compound concentration of 200 M) and the plate was read kinetically (350 nm/450 
nm ex/em) using a PHERAstar microplate reader (BMG LABTECH, Germany). Data for each individual well 
were double referenced to time zero (Time x – time zero fluorescence) and DMSO controls (Compound data  – 
DMSO data at each time point). 
 
 Time (min) 0 5 10 15 20 25 30 35 40 
Ras WT 
Mean 
0 -1688 -2635 -5120 -5606 -5338 -6460 -5891 -6736 
Std. dev. 
0 1016 1230 568 754 935 914 1343 599 
Ras 
(G12V) 
Mean 
0 -1903 -3874 -5164 -6113 -6877 -7303 -7532 -7519 
Std. dev. 
0 358 336 907 726 684 878 959 1041 
Ras 
(G12C) 
Mean 
0 -3536 -4647 -6489 -7956 -8163 -8371 -9221 -8883 
Std. dev. 
0 211 407 1075 724 673 174 839 86 
Ras WT 
(xs GDP) 
Mean 
0 -1581 -2726 -4640 -5153 -5803 -6367 -6450 -7599 
Std. dev. 
0 599 539 725 1059 853 875 1027 1353 
 
 Time (min) 45 50 55 60 65 70 75 80 85 
Ras WT 
Mean 
-6669 -6607 -7348 -6796 -8022 -7327 -8486 -9225 -8592 
Std. dev. 
1505 1609 1685 679 1458 1762 1745 1972 1493 
Ras 
(G12V) 
Mean 
-7800 -7502 -7806 -7477 -8715 -8711 -9593 -9742 -9994 
Std. dev. 
1027 767 847 1037 1039 636 863 1079 929 
Ras 
(G12C) 
Mean 
-9274 -9570 -9753 -9019 -9999 -10285 -10921 -11361 -11571 
Std. dev. 
531 269 467 720 406 1176 519 231 949 
Ras WT 
(xs GDP) 
Mean 
-7551 -7358 -7942 -7911 -8479 -8304 -8126 -8629 -8220 
Std. dev. 
1615 1520 1820 1718 2009 1910 2119 2235 2148 
 
 Time (min) 80 85 90 95 100 105 110 115 120 
Ras WT 
Mean 
-9225 -8592 -9627 -10048 -10261 -10423 -10318 -10639 -10646 
Std. dev. 
1972 1493 1879 1666 1810 2054 2128 2198 1535 
Ras 
(G12V) 
Mean 
-9742 -9994 -9985 -10652 -10683 -10779 -11188 -11272 -11113 
Std. dev. 
1079 929 868 503 1576 759 847 1094 904 
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Ras 
(G12C) 
Mean 
-11361 -11571 -12449 -11510 -12975 -12291 -13238 -13202 -13152 
Std. dev. 
231 949 1141 542 1155 742 990 956 650 
Ras WT 
(xs GDP) 
Mean 
-8629 -8220 -8419 -8431 -8258 -8522 -8452 -8410 -8650 
Std. dev. 
2235 2148 2571 2688 2530 2535 2583 2783 2815 
 
Supplementary Table 3 | Inhibition of SOS-mediated MANT-labelled nucleotide exchange by 12, with wild 
type Ras, and the Ras mutants G12C and G12V. The fourth experiment contained no 12, and instead an 
excess of unlabelled GDP was added. This competes with the MANT-dGDP, acts as a control for the expected 
loss of fluorescence upon MANT-dGDP displacement and represents the rate of exchange of GDP under these 
experimental conditions. 
 
Compound synthesis and characterisation 
1, 2, 4a, 4b, 8, 9 & 10 are commercially available. Synthesis of 7 is described in reference (5). Synthesis and 
characterisation of novel compounds 3, 5, 6, 11, 12, 13 and 14 is described below. 
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2-(2,6-Dimethylphenyl)-4-methylsulfanyl-6-piperazin-1-yl-1,3,5-triazine, 3. A 1 M solution of (2,6-
dimethylphenyl)-magnesium bromide in tetrahydrofuran (5.1 mL, 5.1 mM) was added dropwise to 2,4-dichloro-
6-(methylthio)-1,3,5-triazine (1.00 g, 5.1 mM) in tetrahydrofuran (2.5 mL) at 25 C over a period of 1 minute 
under nitrogen. The resulting mixture was stirred at 67 C for 18 hours. The reaction mixture was allowed to 
cool to room temperature and then quenched with saturated ammonium chloride (5 mL), diluted with ethyl 
acetate and water, shaken, and the organic layer was collected. The organic layer was then washed with saturated 
brine, dried over magnesium sulfate, filtered and evaporated to dryness to give crude product (1.37 g). The crude 
product was purified by flash silica chromatography (80 g column, Grace), with an elution gradient of 5 to 40% 
dichloromethane in isohexane. Pure fractions were evaporated to dryness to afford 2-chloro-4-(2,6-
dimethylphenyl)-6-(methylthio)-1,3,5-triazine (0.788 g, 58.1 %) as a yellow oil which solidified on standing 
under high vacuum overnight. MS (m/z): [MH]
+
 = 266.4; 
1
H NMR (400 MHz, DMSO-d6, 30 C): δ 7.34 - 7.28 
(m, 1H), 7.17 (d, J = 7.8 Hz, 2H), 2.60 (s, 3H), 2.16 (s, 6H). 
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t-Butyl piperazine-1-carboxylate (0.126 g, 0.68 mM) was added in one portion to 2-chloro-4-(2,6-
dimethylphenyl)-6-(methylthio)-1,3,5-triazine (0.150 g, 0.56 mM) and N-ethyl-N-isopropylpropan-2-amine 
(0.187 mL, 1.13 mM) in 2-pentanol (2.6 mL) at 25 C. The resulting mixture was stirred at 100 C for 35 
minutes and allowed to cool to room temperature. The reaction mixture was evaporated to dryness, dissolved in 
dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was added dropwise to the stirred reaction mixture at 25 
C. The reaction mixture was evaporated to dryness and the crude product was purified by ion exchange 
chromatography, using a 10 g SCX-2 column. The desired product was eluted from the column using a solution 
of ammonia in methanol (7 M) and product fractions were evaporated to dryness to afford crude product (0.163 
g). The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5µ silica, 19 
mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% ammonia) and 
acetonitrile as eluents. Fractions containing the desired compound were evaporated to dryness to afford 3 (0.094 
g, 52.9 %) as a colourless gum. HRMS (m/z): [MH]
+
 calcd. for C16H21N5S: 316.15904; found 316.15912; 
1
H 
NMR (400 MHz, DMSO-d6, 21 C): δ 7.21 (dd, J = 8.0, 7.1 Hz, 1H), 7.09 (d, J = 7.5 Hz, 2H), 3.82 - 3.63 (m, 
4H), 2.81 - 2.67 (m, 4H), 2.47 (s, 3H), 2.13 (s, 6H); 
13
C NMR (126 MHz, DMSO-d6, 30 C): δ 180.44, 172.59, 
162.11, 137.73, 134.56, 128.17, 127.39, 45.35, 44.32, 44.20, 19.44, 12.57. 
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N-(4-Aminophenyl)sulfonylcyclopropanecarboxamide, 5. Cyclopropanecarbonyl chloride (0.114 mL, 1.26 
mM) was added to 4-nitrobenzenesulfonamide (0.254 g, 1.26 mM), triethylamine (0.437 mL, 3.14 mM) and 
N,N-dimethylpyridin-4-amine (0.015 g, 0.13 mM) in THF (6 mL) at room temperature under nitrogen. The 
resulting mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with water (50 
mL) and washed with 2 N HCl (50 mL). The aqueous layer was removed and the organics further washed with 
water (50 mL), then brine (50 mL), and finally dried over magnesium sulfate and concentrated under reduced 
pressure onto silica. The crude product was purified by flash silica chromatography, with an elution gradient of 0 
to 5 % methanol in dichloromethane. Pure fractions were evaporated to dryness to afford N-(4-
nitrophenylsulfonyl)cyclopropanecarboxamide (0.350 g, 100 %) as a cream solid. MS (m/z): [MH]
-
 = 269.35; 
1
H 
NMR (400 MHz, DMSO-d6, 21 C): δ 12.10 - 12.00 (m, 1H), 8.43 (d, J = 8.9 Hz, 2H), 8.16 (d, J = 8.9 Hz, 2H), 
1.75 - 1.66 (m, 1H), 0.85 (dq, J = 7.1, 3.7, 3.7, 3.4 Hz, 2H), 0.74 - 0.68 (m, 2H). 
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N-(4-Nitrophenylsulfonyl)cyclopropanecarboxamide (0.290 g, 1.08 mM) was added to a reactor tube and 
dissolved in ethyl acetate (5 mL). This tube was evacuated and purged with nitrogen three times. Palladium 10% 
on carbon (0.017 mg, 0.02 mM) was then added in a single portion and the flask evacuated and purged with 
nitrogen a further three times and with hydrogen twice. The suspension was then stirred under an atmosphere of 
hydrogen at 25 C for 18 hours. The reaction mixture was filtered through celite then the crude product was 
purified by preparative HPLC (Waters SunFire column, 5µ silica, 19 mm diameter, 100 mm length), using 
decreasingly polar mixtures of water (containing 0.1% formic acid) and acetonitrile as eluents. Fractions 
containing the desired compound were evaporated to dryness to afford 5 (0.202 g, 78 %) as a white solid. HRMS 
(m/z): [MH]
+
 calcd. for C10H12N2O3S: 241.06414; found 241.06416; 
1
H NMR (400 MHz, DMSO-d6, 21 C): δ 
11.83 (s, 1H), 7.52 (d, J = 8.7 Hz, 2H), 6.59 (d, J = 8.7 Hz, 2H), 6.08 (s, 2H), 1.73 - 1.58 (m, 1H), 0.80 - 0.72 
(m, 2H), 0.72 - 0.64 (m, 2H); 
13
C NMR (126 MHz, DMSO-d6, 30 C): δ 171.65, 153.50, 129.66, 123.84, 112.21, 
13.59, 8.17. 
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1-(4-Aminophenyl)sulfonylpiperidin-2-one, 6. A mixture of palladium 10% on carbon (0.344 g, 0.32 mM) and 
1-(4-nitrophenylsulfonyl)piperidin-2-one (0.918 g, 3.23 mM) were stirred in a solution of dimethylformamide 
(30 mL) under an atmosphere of hydrogen at 25 C for 24 hours. The reaction mixture was filtered, concentrated 
and diluted with ethyl acetate (75 mL), and washed sequentially with water (2 x 75 mL) and saturated brine (75 
mL). The organic layer was dried over magnesium sulfate, filtered and evaporated to afford desired product, 
which was triturated with acetonitrile, filtered and evaporated to dryness to give 6 (0.610 g, 74 %). HRMS (m/z): 
[MH]
+
 calcd. for C11H14N2O3S: 255.07979; found 255.07985; 
1
H NMR (400 MHz, DMSO-d6, 21 C): δ 7.57 - 
7.51 (m, 2H), 6.62 - 6.55 (m, 2H), 6.13 (s, 2H), 3.79 - 3.72 (m, 2H), 2.31 (t, J = 6.7 Hz, 2H), 1.79 (ddd, J = 9.6, 
7.3, 4.7 Hz, 2H), 1.71 - 1.61 (m, 2H); 
13
C NMR (126 MHz, DMSO-d6, 30 C): δ 169.61, 153.72, 130.31, 130.20, 
123.28, 112.09, 112.00, 46.30, 33.66, 22.72, 19.71. 
S16 
 
 
N
O
NH
2
O
N
O
Br
O
N
O
NHBoc
O
 
3-[3-(Aminomethyl)phenyl]-1-ethyl-pyrrole-2,5-dione, 11. 3-Bromo-1-ethyl-1H-pyrrole-2,5-dione (0.250 g, 
1.23 mM) was added to 4-((tert-butoxycarbonylamino)-methyl)phenylboronic acid (0.308 g, 1.23 mM), 
PdCl2(dppf) (0.067 g, 0.09 mM) and cesium fluoride (0.372 g, 2.45 mM) in dioxane (10 mL) at 20 C. The 
reaction was degassed with nitrogen for 10 minutes and then heated at 70 C for 1 hour. The reaction mixture 
was filtered through celite and the filtrate was concentrated in vacuo. The crude product was purified by flash 
silica chromatography with an elution gradient of 50 to 100% diethyl ether in heptane. Pure fractions were 
evaporated to dryness to afford tert-butyl 4-(1-ethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)benzylcarbamate 
(0.305 g, 75 %) as a yellow gum.  
tert-Butyl 3-(1-ethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)benzylcarbamate (0.320 g, 0.97 mM) was added to 
6.0 N HCl in propan-2-ol (10 mL) and the reaction was stirred for 1 hour. Diethyl ether (10 mL) was then added 
to the reaction and the mixture was stirred for 30 minutes to afford a solid which was collected by filtration and 
dried under vacuum to give 11 (0.102 g, 39.5 %) as a white solid. HRMS (m/z): [MH]
+
 calcd. for C13H14N2O2: 
231.11280 ; found 231.11285; 
1
H NMR (400 MHz, DMSO-d6, 21 C): δ 8.47 (s, 2H), 8.16 (s, 1H), 8.03 (dt, J = 
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7.7, 1.3 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.56 (dd, J = 7.7, 7.7 Hz, 1H), 7.28 (s, 1H), 4.08 (s, 2H), 3.51 (q, J = 
7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, DMSO-d6, 30 C): δ 170.2, 169.9, 142.2, 134.8, 
131.2, 129.0, 129.1, 128.4, 125.5, 42.0, 32.3, 13.6. 
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3-(1-Ethyl-2,5-dioxo-pyrrol-3-yl)benzamide, 12. 3-Bromo-1-ethyl-1H-pyrrole-2,5-dione (0.250 g, 1.23 mM) 
was added to 3-carbamoylphenylboronic acid (0.22 g, 1.35 mM), cesium fluoride (0.372 g, 2.45 mM) and 
PdCl2(dppf) (0.067 g, 0.09 mM) in dioxane (10 mL)/water (1.0 mL). The reaction was heated to 70 C for 1 
hour, then quenched with water (50 mL). The resulting mixture was extracted with dichloromethane (2 x 50 mL) 
then the organic layers were dried over magnesium sulfate, filtered and evaporated to afford a brown solid. The 
crude solid was triturated with dichloromethane to give a solid which was collected by filtration and dried under 
vacuum to give 12 (0.150 g, 50 %) as a white solid. HRMS (m/z): [MH]
+
 calcd. for C13H12N2O3: 231.11280; 
found 231.11285; 
1
H NMR (400 MHz, DMSO-d6, 21 C): δ 8.46 (s, 1H), 8.14 (d, J = 7.8 Hz, 1H), 8.07 (s, 1H), 
7.98 (d, J = 7.8 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.53 (s, 1H), 7.33 (s, 1H), 3.51 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 
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7.2 Hz, 3H); 
13
C NMR (126 MHz, DMSO-d6, 30 C): δ 170.2, 170.0, 167.20, 142.2, 134.9, 131.0, 129.5, 128.9, 
128.8, 127.7, 125.8, 32.3, 13.6. 
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3-Cyano-5-(1-ethyl-2,5-dioxo-pyrrol-3-yl)benzoic acid, 13. tert-Butyl 3-cyano-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzoate (0.538 g, 1.23 mM) was added to PdCl2(dppf) (0.067 g, 0.09 mM), 3-bromo-1-ethyl-
1H-pyrrole-2,5-dione (0.250 g, 1.23 mM) and cesium fluoride (0.372 g, 2.45 mM) in dioxane (15 mL) at 20 C. 
The reaction was degassed with nitrogen for 10 minutes and was then heated at 70 C for 2 hours. Water (1 mL) 
was added and the mixture was heated a further 2 hours at 70 C. The reaction mixture was filtered through 
celite. The filtrate was concentrated and the residue redissolved in dichloromethane. The crude product was 
purified by flash silica chromatography with an elution gradient of 0 to 30% ethyl acetate in heptane. Pure 
fractions were evaporated to dryness to afford tert-butyl 3-cyano-5-(1-ethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-
yl)benzoate (0.250 g, 63 %) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6, 21 C): δ 8.82 (t, J = 1.6 Hz, 
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1H), 8.64 (t, J = 1.6 Hz, 1H), 8.36 (t, J = 1.5 Hz, 1H), 7.55 (s, 1H), 3.53 (q, J = 7.2 Hz, 2H), 1.59 (s, 9H), 1.15 (t, 
J = 7.2 Hz, 3H). 
Trifluoroacetic acid (3.00 mL) was added dropwise to a solution of tert-butyl 3-cyano-5-(1-ethyl-2,5-dioxo-2,5-
dihydro-1H-pyrrol-3-yl)benzoate (0.235 g, 0.72 mM) in dichloromethane (6 mL) cooled to 0 C, then allowed to 
warm to ambient temperature and stirred for 1.5 hours. The reaction mixture was evaporated to dryness to afford 
product as an off-white solid, then triturated with diethyl ether and filtered. The resulting solid was dried under 
vacuum at 40 C overnight to afford 13 (0.112 g, 58 %) as a white solid. HRMS (m/z): [MH]- calcd. for 
C14H10N2O4: 269.05568; found 269.05701; 
1
H NMR (400 MHz, DMSO-d6, 21 C): δ 13.72 (s, 1H), 8.85 (t, J = 
1.5 Hz, 1H), 8.64 (t, J = 1.5 Hz, 1H), 8.38 (t, J = 1.4 Hz, 1H), 7.54 (s, 1H), 3.53 (q, J = 7.2 Hz, 2H), 1.15 (t, 3H); 
13
C NMR (101 MHz, DMSO-d6, 30 C): δ 169.78, 169.56, 165.16, 139.74, 135.70, 133.98, 133.06, 132.64, 
130.57, 127.87, 117.45, 112.64, 32.43, 13.52. 
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3-Chloro-5-(1-ethyl-2,5-dioxo-pyrrol-3-yl)benzamide, 14. 3-Carbamoyl-5-chlorophenylboronic acid (0.244 g, 
1.23 mM) was added to PdCl2(dppf) (0.067 g, 0.09 mM), 3-bromo-1-ethyl-1H-pyrrole-2,5-dione (0.250 g, 1.23 
mM) and cesium fluoride (0.370 g, 2.45 mM) in dioxane (15 mL) and water (1 mL) at 20 C. The reaction was 
degassed with nitrogen for 10 minutes and was then heated at 70 C for 2 hours. The reaction mixture was 
filtered through celite. The filtrate was concentrated and the residue redissolved in dichloromethane. The crude 
product was purified by flash silica chromatography with an elution gradient of 40 to 100% ethyl acetate in 
heptane. Pure fractions were evaporated to dryness and then triturated with diethyl ether to afford 14 (0.104 g, 31 
%) as a pale yellow solid. HRMS (m/z): [MH]
-
 calcd. for C13H11N2O3Cl: 277.03870; found 277.03854; 
1
H NMR 
(400 MHz, DMSO-d6, 21 C): δ 8.43 (t, J = 1.5 Hz, 1H), 8.21 (t, J = 1.7 Hz, 1H), 8.13 (s, 1H), 8.01 - 8.03 (m, 
1H), 7.62 (s, 1H), 7.42 (s, 1H), 3.52 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, DMSO-
d6, 30 C): δ 169.87, 169.68, 165.78, 140.63, 136.68, 133.52, 130.82, 130.32, 128.90, 127.04, 126.39, 32.38, 
13.56. 
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